Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control

checkorphan
Learn more about:
Schistosomiasis
Related Clinical Trial
Monitoring Schistosome Hybrids Under Under Praziquantel Pressure Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa S. Japonicum and Pregnancy Outcomes Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions L-praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda Praziquantel in Children Under Age 4 Schistosoma Haematobium Infections and Praziquantel Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Single-sex Female Controlled Human Schistosomiasis Mansoni Infection An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni) Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal Praziquantel-Pharmacokinetic Study Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Programmes Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study Schistosomiasis in Senegal Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST) Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Arachidonic Acid Treatment Against Schistosomiasis Infection in Children Detection of Schistosomiasis CAA in Travellers After High-risk Water Contact Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Health Benefits of Repeated Treatment in Pediatric Schistosomiasis Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas Women and Children as the Focus for Control of Schistosomiasis Infections in the Irrigations Area of Burkina Faso

Brief Title

Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control

Official Title

Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control

Brief Summary

      Cross-sectional study of prevalence and intensity of schistosome infection in pregnant women,
      follow-up into postpartum, and the association of schistosome infection with haemoglobin
      concentration, compared to a group of non-pregnant women.

Detailed Description

      The objective of this study is to investigate the epidemiology of schistosomiasis and anaemia
      among pregnant and non-pregnant women in Burkina Faso and explore the implications for the
      national schistosomiasis control programme and future studies.

      Specific objectives are:

        -  to determine the prevalence and intensity of schistosome infection in pregnant women
           attending for antenatal care and in non-pregnant women of reproductive age in an area
           which is hyperendemic for S.haematobium infection and in which there is little or no
           S.mansoni infection

        -  to determine the prevalence and intensity of schistosome infection in pregnant women
           attending for antenatal care and in non-pregnant women of reproductive age in an area in
           which S.mansoni infection is common

        -  to determine Haemoglobin concentration in pregnant women attending for antenatal care
           and in non-pregnant women of reproductive age in the regions described above

        -  to investigate the association between infection and haemoglobin concentration in
           pregnant and non-pregnant women

        -  to determine the prevalence of other parasitic infections in pregnant women and
           non-pregnant women including hookworms, ascaris, trichuris and malaria

        -  to demonstrate the research team's ability to follow-up pregnant women recruited at
           antenatal care clinics onto the postpartum period

Study Type

Observational

Condition

Schistosomiasis

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment

200

Start Date

January 2007

Completion Date

January 2009

Primary Completion Date

January 2009

Eligibility Criteria

        Inclusion Criteria:

          -  Pregnant women attending for ANC

          -  Non-pregnant women age 15-45 years accompanying relatives or children to the health
             centres or for immunization

Gender

Female

Ages

15 Years - 45 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Seydou Touré, MD, ,

Location Countries

Burkina Faso

Location Countries

Burkina Faso

Administrative Informations

NCT ID

NCT00463632

Organization ID

SRP-BF-ST-06

Study Sponsor

DBL -Institute for Health Research and Development

Collaborators

 Centre Muraz

Study Sponsor

Seydou Touré, MD, Principal Investigator, The National Schistosomiasis Control Program Burkina Faso

Verification Date

January 2010